family with sequence similarity 239 member CGenealiases: []
Q-omics provides the consensus-scored FAM239C profile across patient tissues and cancer cell-line models. FAM239C expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, FAM239C is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, FAM239C RNA expression shows 3,935 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight OV, KIRC, and UCEC as cancer lineages where FAM239C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM239C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM239C survival associations across molecular data types. FAM239C RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM239C RNA expression–survival associations across cancer types. High FAM239C expression shows unfavorable associations in DLBC and LUAD, but favorable associations in OV, BLCA, ESCA and CESC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify OV as the clearest survival context for FAM239C RNA expression.
This table summarizes FAM239C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM239C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM239C shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, LUAD, CHOL and LUSC. The KIRC box plot shows higher FAM239C RNA expression in tumor versus normal tissue (log2 FC = +0.278, t-test p = .001).
This table shows molecular features associated with FAM239C in patient tissues and cancer cell lines. In patient samples, FAM239C shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
